Circulating levels of GDF-15 for predicting cardiovascular and cancer morbidity and mortality in type 2 diabetes: Findings from Da Qing IGT and Diabetes Study
单位:[1]Chinese Acad Med Sci & Peking Union Med Coll, Fuwai Hosp, Endocrinol Ctr, Beijing, Peoples R China[2]Da Qing First Hosp, Dept Cardiol, Daqing, Peoples R China[3]China Japan Friendship Hosp, Dept Endocrinol, Beijing, Peoples R China
Aim: To investigate the relationship between circulating growth differentiation factor (GDF-15) levels and the risk of cardiovascular disease and cancer in people with diabetes.Methods: Totally, 510 participants with type 2 diabetes were enrolled from the long-term follow-up of the Da Qing Impaired Glucose Tolerance (IGT) and Diabetes Study (2006-2009). Plasma GDF-15 levels were assessed. Outcomes of cardiovascular events, cancer, and related death were followed up until 2016.Results: Over a 7.5-year follow-up period, 143 (28.0%) of the participants died, and 155 and 56 experienced cardiovascular events and cancer respectively. Multivariable Cox analysis showed that higher circulating GDF-15 levels were significantly associated with the increased risk of cardiovascular and cancer death. The HRs after adjustment of traditional confounders were 1.90 (95%CI 1.31-2.74) and 2.50 (95%CI 1.34-4.67) respectively for an increase in one unit of loge transformed GDF-15 (pg/ml). The cause-specific hazard model analysis further confirmed the results after adjusting the same confounders. In addition, the higher GDF-15 levels were also significantly associated with the increased risk of cardiovascular events (HR=1.35, 95%CI: 1.04-1.76) and cancer (HR=1.62, 95%CI 1.06-2.47).Conclusions: Elevated circulating levels of GDF-15 predicted a significant increase in the dual risk of cancer and cardiovascular diseases in Chinese people with type 2 diabetes. Thus, it may be a potential predictor of these outcomes in people with diabetes.(c) 2022 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
基金:
US Centers for Disease Control and Prevention (CDC) /WHO Cooperative Agreement [U58/CCU424123-01-02]; China-Japan Friendship Hospital; Da Qing First Hospital; US CDC-Chinese Center for Disease Control and Prevention Cooperative Agreement [5U19GH000636-05]; National Center for Cardiovascular Diseases; Fuwai Hospital; Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (CIFMS) [2020-I2M-2-006]
第一作者单位:[1]Chinese Acad Med Sci & Peking Union Med Coll, Fuwai Hosp, Endocrinol Ctr, Beijing, Peoples R China
通讯作者:
通讯机构:[1]Chinese Acad Med Sci & Peking Union Med Coll, Fuwai Hosp, Endocrinol Ctr, Beijing, Peoples R China[3]China Japan Friendship Hosp, Dept Endocrinol, Beijing, Peoples R China[*1]Chinese Acad Med Sci & Peking Union Med Coll, Fuwai Hosp, Endocrinol Ctr, 167 North Lishi Rd, Beijing 100037, Peoples R China
推荐引用方式(GB/T 7714):
Qian Xin,He Siyao,Shen Xiaoxia,et al.Circulating levels of GDF-15 for predicting cardiovascular and cancer morbidity and mortality in type 2 diabetes: Findings from Da Qing IGT and Diabetes Study[J].DIABETES & METABOLISM.2022,48(6):doi:10.1016/j.diabet.2022.101380.
APA:
Qian, Xin,He, Siyao,Shen, Xiaoxia,Shi, Na,Gong, Qiuhong...&Li, Guangwei.(2022).Circulating levels of GDF-15 for predicting cardiovascular and cancer morbidity and mortality in type 2 diabetes: Findings from Da Qing IGT and Diabetes Study.DIABETES & METABOLISM,48,(6)
MLA:
Qian, Xin,et al."Circulating levels of GDF-15 for predicting cardiovascular and cancer morbidity and mortality in type 2 diabetes: Findings from Da Qing IGT and Diabetes Study".DIABETES & METABOLISM 48..6(2022)